Proteome screening of pleural effusions identifies IL1A as a diagnostic biomarker for non-small cell lung cancer

Biochemical and Biophysical Research Communications

Volumn 457, Issue 2, 2015, Pages 177-182

  Li, Yuanyuan ^a,b   Lian, Hengning ^a,c   Jia, Qingzhu ^a,b   Wan, Ying ^a,b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chongqing Key Laboratory of Cytomics   (China)

^c CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

IL1A; Non small cell cancer; NSCLC; Pleural effusion; Proteomics

Indexed keywords

INTERLEUKIN 1ALPHA; PROTEOME; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER DIAGNOSIS; CELL ADHESION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LUNG METASTASIS; LUNG TUBERCULOSIS; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEOMICS; SCREENING; TANDEM MASS SPECTROMETRY; TUMOR GROWTH; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; PLEURAL EFFUSION; PROCEDURES; REPRODUCIBILITY; TUBERCULOSIS;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-1ALPHA; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUBERCULOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84921755842     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.12.083     Document Type: Article

References (52)

1. M. Reck, S. Popat, N. Reinmuth, D. De Ruysscher, K.M. Kerr, S. Peters, Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol./EMSO 25 (Suppl. 3) (2014) iii27-iii39.
2. R. Siegel, D. Naishadham, A. Jemal, Cancer statistics, 2013, CA Cancer J. Clin. 63 (2013) 11-30.
3. J.R. Molina, P. Yang, S.D. Cassivi, S.E. Schild, A.A. Adjei, Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship, Mayo Clin. Proc. 83 (2008) 584-594.
4. J. Kisluk, M. Ciborowski, M. Niemira, A. Kretowski, J. Niklinski, Proteomics biomarkers for non-small cell lung cancer, J. Pharm. Biomed. Anal. (2014).
5. T.D. Veenstra, T.P. Conrads, B.L. Hood, A.M. Avellino, R.G. Ellenbogen, R.S. Morrison, Biomarkers: mining the biofluid proteome, Mol. Cell. Proteomics 4 (2005) 409-418.
6. D.M. Good, V. Thongboonkerd, J. Novak, J.L. Bascands, J.P. Schanstra, J.J. Coon, A. Dominiczak, H. Mischak, Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future, J. Proteome Res. 6 (2007) 4549-4555.
7. S.M. Ahn, R.J. Simpson, Body fluid proteomics: prospects for biomarker discovery, Proteomics Clin. Appl. 1 (2007) 1004-1015.
8. R.H. Young, Meigs' Syndrome: Dr. Richard Cabot's Hidden First American Case, Int. J. Surg. Pathol. 8 (2000) 165-168.
9. S.A. Sahn, Management of malignant pleural effusions, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace/Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Universita di Napoli, Secondo ateneo 56 (2001) 394-399.
10. A.M. Rodriguez-Pineiro, S. Blanco-Prieto, N. Sanchez-Otero, F.J. Rodriguez-Berrocal, M.P. de la Cadena, On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion, J. Proteomics 73 (2010) 1511-1522.
11. Z. Wang, C. Wang, X. Huang, Y. Shen, J. Shen, K. Ying, Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients, Biochim. Biophys. Acta 2012 (1824) 692-700.
12. K. Yanagisawa, Y. Shyr, B.J. Xu, P.P. Massion, P.H. Larsen, B.C. White, J.R. Roberts, M. Edgerton, A. Gonzalez, S. Nadaf, J.H. Moore, R.M. Caprioli, D.P. Carbone, Proteomic patterns of tumour subsets in non-small-cell lung cancer, Lancet 362 (2003) 433-439.
13. G. Baronzio, G. Parmar, M. Baronzio, M. Kiselevsky, Tumor interstitial fluid: proteomic determination as a possible source of biomarkers, Cancer Genomics Proteomics 11 (2014) 225-237.
14. Y. Cai, Q. Yang, Y. Tang, M. Zhang, H. Liu, G. Zhang, Q. Deng, J. Huang, Z. Gao, B. Zhou, C.G. Feng, X. Chen, Increased complement C1q level marks active disease in human tuberculosis, PLoS ONE 9 (2014) e92340.
15. S. Srivatsan, M. Swiecki, K. Otero, M. Cella, A.S. Shaw, CD2-associated protein regulates plasmacytoid dendritic cell migration, but is dispensable for their development and cytokine production, J. Immunol. 191 (2013) (1950) 5933-5940.
16. G.H. Li, P.D. Arora, Y. Chen, C.A. McCulloch, P. Liu, Multifunctional roles of gelsolin in health and diseases, Med. Res. Rev. 32 (2012) 999-1025.
17. Y.C. Tyan, P.C. Liao, Proteomics analysis of serous fluids and effusions: pleural, pericardial, and peritoneal, Proteomics Clin. Appl. 1 (2007) 834-844.
18. J. Yang, D. Tan, H.L. Asch, H. Swede, G. Bepler, J. Geradts, K.B. Moysich, Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer, Lung Cancer 46 (2004) 29-42.
19. P. Indovina, E. Marcelli, F. Pentimalli, P. Tanganelli, G. Tarro, A. Giordano, Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery, Mass Spectrom. Rev. 32 (2013) 129-142.
20. H. Kawai, Y. Minamiya, N. Takahashi, Prognostic impact of S100A9 overexpression in non-small cell lung cancer, Tumour Biol. 32 (2011) 641-646.
21. Y.F. Liu, Y.H. Chen, M.Y. Li, P.F. Zhang, F. Peng, G.Q. Li, Z.Q. Xiao, Z.C. Chen, Quantitative proteomic analysis identifying three annexins as lymph node metastasis-related proteins in lung adenocarcinoma, Medical Oncol. 29 (2012) 174-184.
22. C. Garlanda, C.A. Dinarello, A. Mantovani, The interleukin-1 family: back to the future, Immunity 39 (2013) 1003-1018.
23. P. Rider, Y. Carmi, E. Voronov, R.N. Apte, Interleukin-1alpha, Semin. Immunol. 25 (2013) 430-438.
24. N.A. Turner, A. Das, P. Warburton, D.J. O'Regan, S.G. Ball, K.E. Porter, Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H1117-H1127.
25. E. Voronov, D.S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C.A. Dinarello, R.N. Apte, IL-1 is required for tumor invasiveness and angiogenesis, Proc. Natl. Acad. Sci. USA 100 (2003) 2645-2650.
26. D.M. Elaraj, D.M. Weinreich, S. Varghese, M. Puhlmann, S.M. Hewitt, N.M. Carroll, E.D. Feldman, E.M. Turner, H.R. Alexander, The role of interleukin 1 in growth and metastasis of human cancer xenografts, Clin. Cancer Res. 12 (2006) 1088-1096.
27. H. Sawai, H. Funahashi, M. Yamamoto, Y. Okada, T. Hayakawa, M. Tanaka, H. Takeyama, T. Manabe, Interleukin-1alpha enhances integrin alpha(6)beta(1) expression and metastatic capability of human pancreatic cancer, Oncology 65 (2003) 167-173.
28. R. Mazzolini, H. Dopeso, S. Mateo-Lozano, W. Chang, P. Rodrigues, S. Bazzocco, et al., Brush border myosin Ia has tumor suppressor activity in the intestine, Proc. Natl. Acad. Sci. USA 109 (2012) 1530-1535.
29. R. Mazzolini, P. Rodrigues, S. Bazzocco, H. Dopeso, A.M. Ferreira, S. Mateo-Lozano, et al., Brush border myosin Ia inactivation in gastric but not endometrial tumors, Int. J. Cancer J. Int. Cancer 132 (2013) 1790-1799.
30. P.A. Klenotic, P. Huang, J. Palomo, B. Kaur, E.G. Van Meir, M.A. Vogelbaum, et al., Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin, Am. J. Pathol. 176 (2010) 2039-2050.
31. R. Simantov, M. Febbraio, R. Crombie, A.S. Asch, R.L. Nachman, R.L. Silverstein, Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1, J. Clin. Investig. 107 (2001) 45-52.
32. A. Thulin, M. Ringvall, A. Dimberg, K. Karehed, T. Vaisanen, M.R. Vaisanen, et al., Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein, Mol. Cancer Res. 7 (2009) 1792-1802.
33. J. Wu, X. Xie, Y. Liu, J. He, R. Benitez, R.J. Buckanovich, et al., Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS, J. Proteome Res. 11 (2012) 4541-4552.
34. M. Ringvall, A. Thulin, L. Zhang, J. Cedervall, N. Tsuchida-Straeten, W. Jahnen-Dechent, et al., Enhanced platelet activation mediates the accelerated angiogenic switch in mice lacking histidine-rich glycoprotein, PLoS ONE 6 (2011) e14526.
35. E.M. El-Omar, M. Carrington, W.H. Chow, K.E. McColl, J.H. Bream, H.A. Young, et al., Interleukin-1 polymorphisms associated with increased risk of gastric cancer, Nature 404 (2000) 398-402.
36. B. Charbonneau, M.S. Block, W.R. Bamlet, R.A. Vierkant, K.R. Kalli, Z. Fogarty, et al., Risk of ovarian cancer and the NF-kappaB pathway: genetic association with IL1A and TNFSF10, Cancer Res. 74 (2014) 852-861.
37. G. Rodriguez-Berriguete, B. Sanchez-Espiridion, J.R. Cansino, G. Olmedilla, P. Martinez-Onsurbe, M. Sanchez-Chapado, et al., Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-alpha signaling pathways in prostate cancer, Cytokine 64 (2013) 555-563.
38. M.A. Hildebrandt, R. Komaki, Z. Liao, J. Gu, J.Y. Chang, Y. Ye, et al., Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer, PLoS ONE 5 (2010) e12402.
39. R. Frischknecht, C.I. Seidenbecher, Brevican: a key proteoglycan in the perisynaptic extracellular matrix of the brain, Int. J. Biochem Cell Biol. 44 (2012) 1051-1054.
40. B. Hu, L.L. Kong, R.T. Matthews, M.S. Viapiano, The proteoglycan Brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility, J. Biol. Chem. 283 (2008) 24848-24859.
41. M. Faryna, C. Konermann, S. Aulmann, J.L. Bermejo, M. Brugger, S. Diederichs, et al., Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis, FASEB J. 26 (2012) 4937-4950.
42. Y. Sato, N. Yamamoto, H. Kunitoh, Y. Ohe, H. Minami, N.M. Laird, et al., Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel, J. Thorac. Oncol. 6 (2011) 132-138.
43. Q. Zhou, M.E. Munger, R.G. Veenstra, B.J. Weigel, M. Hirashima, D.H. Munn, et al., Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia, Blood 117 (2011) 4501-4510.
44. X. Gao, Y. Zhu, G. Li, H. Huang, G. Zhang, F. Wang, et al., TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression, PLoS ONE 7 (2012) e30676.
45. R.H. McMahan, L. Golden-Mason, M.I. Nishimura, B.J. McMahon, M. Kemper, T.M. Allen, et al., Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocytedirected in vitro cytotoxicity, J. Clin. Investig. 120 (2010) 4546-4557.
46. L.M. Greene, W.O. Twal, M.J. Duffy, E.W. McDermott, A.D. Hill, N.J. O'Higgins, et al., Elevated expression and altered processing of fibulin-1 protein in human breast cancer, Br. J. Cancer 88 (2003) 871-878.
47. Y. Wen, S.F. Giardina, D. Hamming, J. Greenman, E. Zachariah, M.D. Bacolod, et al., GROalpha is highly expressed in adenocarcinoma of the colon and downregulates fibulin-1, Clin. Cancer Res. 12 (2006) 5951-5959.
48. A. Wlazlinski, R. Engers, M.J. Hoffmann, C. Hader, V. Jung, M. Muller, et al., Downregulation of several fibulin genes in prostate cancer, Prostate 67 (2007) 1770-1780.
49. Y.Y. Cheng, H. Jin, X. Liu, J.M. Siu, Y.P. Wong, E.K. Ng, et al., Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer, Br. J. Cancer 99 (2008) 2083-2087.
50. K. Pietraszek, S. Brezillon, C. Perreau, M. Malicka-Blaszkiewicz, F.X. Maquart, Y. Wegrowski, Lumican - derived peptides inhibit melanoma cell growth and migration, PLoS ONE 8 (2013) e76232.
51. V.J. Coulson-Thomas, Y.M. Coulson-Thomas, T.F. Gesteira, C.A. Andrade de Paula, C.R. Carneiro, V. Ortiz, et al., Lumican expression, localization and antitumor activity in prostate cancer, Exp. Cell Res. 319 (2013) 967-981.
52. C. Panis, L. Pizzatti, A.C. Herrera, R. Cecchini, E. Abdelhay, Putative circulating markers of the early and advanced stages of breast cancer identified by highresolution label-free proteomics, Cancer Lett. 330 (2013) 57-66.